Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
1.49% $8.17
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 560.47 mill |
EPS: | -2.67 |
P/E: | -3.06 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 68.60 mill |
Avg Daily Volume: | 4.43 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.06 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.52x |
Company: PE -3.06 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-1.148 (-114.05%) $-9.32 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 7.33 - 9.01 ( +/- 10.28%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-07 | Boyle Scott N | Buy | 115 000 | Stock Option (Right to Buy) |
2024-03-07 | Boyle Scott N | Sell | 115 000 | Stock Option (Right to Buy) |
2024-03-07 | Fisher Stewart | Buy | 118 000 | Stock Option (Right to Buy) |
2024-03-07 | Fisher Stewart | Buy | 94 950 | Stock Option (Right to Buy) |
2024-03-07 | Fisher Stewart | Sell | 118 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
60.56 |
Last 98 transactions |
Buy: 4 666 481 | Sell: 1 001 966 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $8.17 (1.49% ) |
Volume | 1.866 mill |
Avg. Vol. | 4.43 mill |
% of Avg. Vol | 42.15 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $5.63 | N/A | Active |
---|
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.